Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 3Phase 1 2Phase NA 1Phase EARLY_PHASE1 1Phase 3 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Prostatic Neoplasms 2Glioblastoma 2Stomach Neoplasms 1Pancreatic Neoplasms 1Oligodendroglioma 1Neoplasms 1Mycosis Fungoides 1Melanoma 1Lymphoma, Large B-Cell, Diffuse 1Head and Neck Carcinoma of Unknown Primary 1Gliosarcoma 1Glioma, Subependymal 1Glioma 1Gastrointestinal Neoplasms 1Esophageal Squamous Cell Carcinoma 1Ependymoma 1Central Nervous System Neoplasms 1Astrocytoma 1

Interventions

motexafin gadolinium 1irinotecan sucrosofate 1bemcentinib 1Vincristine 1Temozolomide 1Rituximab 1Radiotherapy 1Radiation 1Procarbazine 1Postoperative Period 1Pemetrexed 1Nivolumab 1Methotrexate 1Memantine 1Irinotecan 1Immunotherapy 1Donepezil 1Cytarabine 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Central Nervous System Neoplasms × Radiation × Clear all
NCT03554707 2026-05-08

SGT-53 in Children With Recurrent or Progressive CNS Malignancies

SynerGene Therapeutics, Inc.

Phase EARLY_PHASE1 Withdrawn
CNS

Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡